首页> Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer> Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?

Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?

导出原文传递

翻译打印收藏纠错

第一作者： Tri,Le

第一单位： Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.

作者： Tri,Le ^[1] ; John D,Minna ^[2] ; David E,Gerber ^[3]

作者单位： Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas. ^[1] Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. ^[2] Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: david.gerber@utsouthwestern.edu. ^[3]

医学主题词癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);人类(Humans);免疫疗法(Immunotherapy);肺肿瘤(Lung Neoplasms);肺炎(Pneumonia)

DOI 10.1016/j.jtho.2018.12.017

PMID 30782379

发布时间 2019-11-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交